Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 for Opioid Withdrawal
NCT05712707Phase 2Active, not recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine in opioid withdrawal, sponsored by New York State Psychiatric Institute. Started Feb 2023; status: active, not recruiting.
02
Drugs
dexmedetomidine
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT05712707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712707.